# A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

> **NCT07733765** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 336 (estimated)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Ritlecitinib 100 mg
- **DRUG:** Ritlecitinib 50 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07733765
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-04-26
- **Final completion:** 2028-04-26
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733765, "A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*